| 000 | 01813 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513141602.0 | ||
| 264 | 0 | _c19980512 | |
| 008 | 199805s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1998.16.4.1425 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPehamberger, H | |
| 245 | 0 | 0 |
_aAdjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cApr 1998 |
||
| 300 |
_a1425-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdjuvants, Immunologic |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xpathology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aSkin Neoplasms _xpathology |
| 700 | 1 | _aSoyer, H P | |
| 700 | 1 | _aSteiner, A | |
| 700 | 1 | _aKofler, R | |
| 700 | 1 | _aBinder, M | |
| 700 | 1 | _aMischer, P | |
| 700 | 1 | _aPachinger, W | |
| 700 | 1 | _aAuböck, J | |
| 700 | 1 | _aFritsch, P | |
| 700 | 1 | _aKerl, H | |
| 700 | 1 | _aWolff, K | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 16 _gno. 4 _gp. 1425-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1998.16.4.1425 _zAvailable from publisher's website |
| 999 |
_c9519465 _d9519465 |
||